There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > BAFF


Brief Information

Name:B-cell-activating factor/B lymphocyte stimulator
Target Synonym:DTL,Dendritic Cell-Derived TNF-Like Molecule,CD257,B-Cell-Activating Factor,B Lymphocyte Stimulator,B-Lymphocyte Stimulator,B-Cell Activating Factor,Tumor Necrosis Factor Ligand 7A,TNF And ApoL-Related Leukocyte Expressed Ligand 1,BAFF,BLYS,Delta BAFF,TAL
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

BAF-H52D4-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human BAFF, His,Flag Tag, active trimer (Cat. No. BAF-H52D4) stimulates proliferation of mouse spleen cells. The EC50 for this effect is 1.97-2.90 ng/mL (Routinely tested).

BAF-H5261-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human BAFF, Fc Tag, active trimer (Cat. No. BAF-H5261) stimulates proliferation of mouse spleen cells. The EC50 for this effect is 4.91-9.81 ng/mL (Routinely tested).


Human BAFFR Protein, Fc Tag (Cat. No. BAR-H5257) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human BAFF Protein, His,Flag Tag (Cat. No. BAF-H52D4) with an affinity constant of 5.54 nM as determined in a SPR assay (Biacore T200) (Routinely tested).


Immobilized Human BAFF, Fc Tag, active trimer (Cat. No. BAF-H5261) on CM5 Chip can bind Human TACI/TNFRSF13B, Fc Tag (Cat. No. TAI-H5256) with an affinity constant of 0.658 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Synonym Name



B-cell activating factor (BAFF) is also known as tumor necrosis factor ligand superfamily member 13B , TNFSF13B, BAFF, B Lymphocyte Stimulator (BLyS) , cluster of differentiation 257 (CD257), DTL, TNF- and APOL-related leukocyte expressed ligand (TALL-1), THANK, TNFSF20, ZTNF4, and is a  cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This cytokine is a ligand for receptors TNFRSF13B/TACI, TNFRSF17/BCMA, and TNFRSF13C/BAFFR. This cytokine is expressed in B cell lineage cells, and acts as a potent B cell activator. It has been also shown to play an important role in the proliferation and differentiation of B cells. It is expressed as transmembrane protein on various cell types including monocytes, dendritic cells and bone marrow stromal cells. BAFF is the natural ligand of three unusual tumor necrosis factor receptors named BAFF-R, TACI, and BCMA, all of which have differing binding affinities for it. These receptors are expressed mainly on mature B lymphocytes (TACI is also found on a subset of T-cells and BCMA on plasma cells). TACI binds worst since its affinity is higher for a protein similar to BAFF, called a proliferation-inducing ligand (APRIL). BCMA displays an intermediate binding phenotype and will work with either BAFF or APRIL to varying degrees. Signaling through BAFF-R and BCMA stimulates B lymphocytes to undergo proliferation and to counter apoptosis. All these ligands act as heterotrimers (i.e. three of the same molecule) interacting with heterotrimeric receptors, although BAFF has been known to be active as either a hetero- or homotrimer. BAFF acts as a potent B cell activator and has been shown to play an important role in the proliferation and differentiation of B cells. 

Clinical and Translational Updates

Related Molecule

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Belimumab GSK-1550188; HGS-1006; BmAb Approved Glaxosmithkline Plc Benlysta, 倍力腾 EU Lupus Nephritis Glaxosmithkline (Ireland) Ltd 2011-03-09 Arthritis, Rheumatoid; Vasculitis; Purpura; Lupus Nephritis; Glomerulonephritis, Membranous; Lupus Erythematosus, Systemic Details
Telitacicept RCT-18; RC-18; RCT18; RC18 Approved Rc Biotechnologies Ltd 泰爱 Mainland China Lupus Erythematosus, Systemic RemeGen Co Ltd 2021-03-09 Multiple Sclerosis, Relapsing-Remitting; Myasthenia Gravis; Glomerulonephritis, IGA; Arthritis, Rheumatoid; Sjogren's Syndrome; Multiple Sclerosis; Lupus Erythematosus, Systemic; Neuromyelitis Optica Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
UBP-1213 UBP-1213 Phase 1 Clinical Wuhan Huaxin Kangyuan Biomedicine Co Ltd, Shanghai Junshi Biosciences Co Ltd Lupus Erythematosus, Systemic Details
Atacicept TACI-Ig Phase 3 Clinical Zymogenetics Glomerulonephritis, IGA; Arthritis, Rheumatoid; Optic Neuritis; Multiple Sclerosis; Lupus Nephritis; Multiple Myeloma; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rozibafusp alfa AMG-570; MEDI-0700 Phase 2 Clinical Amgen Inc Arthritis, Rheumatoid; Lupus Erythematosus, Systemic Details

This web search service is supported by Google Inc.